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Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms 
(MPN),
1
 that can progress to blast phase
2
 and to post-PV (PPV) myelofibrosis (MF) and post-ET 
(PET) MF,
3
 from now on referred to as secondary myelofibrosis (SMF). Progression may depend by 
many predisposition factors as higher JAK2 V617F allele burden, abnormal karyotype (AK), SRSF2 
mutation, bone marrow fibrosis grade 1, advanced age, disease duration, leukocytosis, and 
splenomegaly. 
4-6
 Cytogenetic analysis is performed rarely, making its relevance in SMF unknown.  
 
The MYSEC project (Myelofibrosis Secondary to PV and ET Collaboration) is a retrospective project 
based on 781 IWGMRT-diagnosed SMF patients, that already disclosed SMF mutation profile
7
 and 
prognostication.
8
 Here, we analyzed cytogenetic data available at the time of SMF (376 cases: 188 
PET MF, 188 PPV MF) in order to study karyotype-genotype-clinical phenotype correlations and 
the impact on prognosis. G-banding with trypsin
 
was the standard technique for chromosome 
analysis with at least 20 metaphases described.
 
The study was approved by the Institutional 
Review Board of each Institution and conducted in accordance with the principles of the 
Declaration of Helsinki. Continuous baseline values were compared via the Wilcoxon rank sum test 
and categorical feature counts via the Fisher’s exact tests. The Holm correction for multiple testing 
was used for post-hoc analysis. Time-to-event analyses were performed via Kaplan-Meier curves, 
using log-rank tests for comparisons and semi-parametric Cox models for regression. Tests for 
differences in normal (NK) versus abnormal karyotypes (AK) were conducted first; where a 
significant departure from the null was found, the individual abnormal karyotypes were compared 
with respect to the normal one. 
 
Within 376 SMF, AK was found in 128 (34%) patients. Within chromosomal abnormalities, 72 
(56%) were sole abnormality, 26 (20%) complex karyotype (of which 11 -8.5%- were MK), 22 (17%) 
double abnormalities and eight abnormal karyotypes not further specified. List of involved 
chromosomes, according to single, double and complex chromosomal abnormalities is shown in 
Table 1S. Among the sole abnormalities, the most prevalent were: 20q- (18 cases, 25%), 13q- (15 
cases, 21%), +8 (6 cases, 8%) and +9 (4 cases, 6%). Other individual alterations were present in less 
than 5% of patients.  
 
Table 1 reports demographics of SMF patients according to AK and normal karyotype (NK) status. 
AK clustered differently according to the type of diagnosis as was found in 76 (40%) patients 
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within PPV MF and in 52 (28%) with PET MF (P = .012). No relationship was found with advanced 
age, leukocyte count, hemoglobin value, and bone marrow fibrosis grade (2 vs. 3). On the 
contrary, lower platelet counts were associated with AK (P = .004). Post-hoc tests of platelets 
counts versus karyotype found significantly lower platelet counts in monosomal karyotype (MK) 
(median value, 178 x10
9
/L) compared to NK (median value, 365 x10
9
/L, P = .02) and to sole 
abnormality (median value, 319 x10
9
/L, P = .04). We found also a relationship between AK and 
higher percentage of circulating blast cells (P < .001) and larger spleen size (P = .015). Sixty-three 
(51%) with AK and 91 (37%) with NK had constitutional symptoms (P = .013). Overall, AK confers a 
more advanced clinical phenotype. 
 
In 339 patients, we analyzed the correlation between cytogenetic profile and driver mutation. 
Chromosomal abnormalities were described in 12 (23%) out of 52 CALR-mutated patients, in 28 
(31%) out of 90 JAK2-mutated PET MF, in 73 (41%) out of 178 JAK2-mutated PPV MF, in three 
(23%) out of 13 MPL-mutated and in no TN case. Post hoc test revealed that AK was differently 
distributed between JAK2-PPV MF (41%) and CALR (23%) (P = .002). However, this significant 
association is lost after adjusting for multiple comparisons (minimum P > .2). 
 
Thrombotic event after SMF diagnosis occurred in 40 patients and 27 transformed to blast phase 
(BP). Overall, we did not disclose any relationship between AK and thrombosis (P = .66) or blast 
phase (P = .4). However, considering AK types individually, we found that patients with a complex 
karyotype (CK) had a 3.8-fold (95% CI: 1.3-11.2; P = .01) higher risk of developing blast phase than 
those without. 
 
Median survival was significantly different between NK and AK patients and estimated at 10.1 
years (95% CI: 8.1-not reached -NR-) and 6.1 years (95% CI: 4.8-NR), respectively (P = .012, Figure 
1). The difference retained its statistical significance in Cox regressions adjusted for SMF type (P = 
.02), but when adding MYSEC-PM risk strata in the multivariate analysis, AK per se did not disclose 
any effect on survival (P = .5). Post-hoc log-rank tests comparing the effect of different cytogenetic 
abnormalities found that patients with MK, those with CK without MK and those with CK had 
worse survival with a median estimate of 2.1 years (95% CI: 1-NR), 3.4 years (95% CI: 2.6-NR), and 
2.7 years (95% CI: 2-NR), respectively. All groups had inferior survival when compared to NK, sole 
or double abnormalities (P < .001). Of note, MK patients had worse survival (hazard ratio 3.7, 95% 
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CI: 1.2-10.8) independently of their MYSEC-PM risk group, as shown by stratification by score 
groups (P = .018). Figure 2 illustrates survival estimates according to cytogenetic profile. 
 
Concerning the distribution of cytogenetic status within the MYSEC-PM risk stratification,
8
 a 
significant association was found between higher MYSEC-PM risk categories and AK (P = .006, 
Supplementary Figure 1S). Chromosomal abnormalities were found in 13 out of 69 low risk (19%), 
51 out of 140 intermediate-1 risk (36%), 22 out of 61 intermediate-2 risk (36%) and 17 out of 33 
high risk (52%) patients. 
 
Until now, SMF has been managed similarly to PMF; however, differences between the two 
conditions have been recently identified in terms of clinical presentation as well as of survival 
estimates or IPSS/DIPSS prognostic model applicability.
9,10
 As a consequence, more detailed 
information on SMF is indeed necessary. 
 
We found an abnormal karyotype in one third of patients at SMF diagnosis, similar to the numbers 
found in PMF by the MD Anderson Cancer Center (35%),
9
 by the Mayo Clinic (37%)
11
 and by the 
IPSS (30%) investigators. In MYSEC cases with chromosomal abnormalities, 56% were sole, 20% 
complex (8.5% MK) and 17% double. The most prevalent single abnormalities were 20q-, 13q-, +8 
and +9, accounting for 5%, 4%, 2% and 1% of the whole series (n=376), respectively. This figure 
parallels data on PV and ET. In fact, a recent analysis on 107 PV at diagnosis showed 20q-, +8, and 
+9 in 3%, 3%, and 5%, respectively. Another study on 196 PV found 20q-, 13q-, +8, and +9 in 3%, 
0.5%, 3%, 0.5%,
12
 respectively and in ET all are present in less than 1%.
13
 This suggests that these 
most frequent cytogenetic abnormalities found at the time of SMF are not pathogenic events of 
SMF, but are a consequence of the PV and ET phase. This seems clear also from recent sequential 
data on cytogenetics in PV and PPV MF.
14
 However, we cannot exclude that small clones at 
diagnosis can become dominant at progression to SMF, and the clonal dominance may indeed be 
pathogenic in SMF. In SMF we reported a high rate of double abnormalities (17%) and complex 
karyotype (20%). This differs from data obtained in the PV and ET phase. Within a cohort of 107 PV 
patients assessed at diagnosis, double abnormalities were recorded in two, and CK in one, 
14
 in 
agreement with other studies: less than 2% in PV
12
 and less than 1% in ET.
13
 Hence, finding double 
abnormalities and complex karyotype seems to be more typical of SMF than of PV and ET. As most 
double abnormalities found in the MYSEC dataset are in individual patients, it is not possible to 
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suggest which one is most pathogenetic. In two large cohorts of PMF patients, double 
abnormalities and complex karyotype are present in 17% and 11%,
15
  and in 8% and 5%,
9
 
respectively.  
 
Survival of NK patients more closely reflected a benign disease (median value of 10.1 years), while 
that of AK patients an aggressive one (median value of 6.1 years). Of note, MYSEC-PM still remain 
the more precise way to stratify survival, as suggested by multivariate analysis including MYSEC-
PM strata and abnormal/normal karyotype. Our study identified two SMF cohorts with very short 
survival: patients with complex karyotype (median value, 2.7 years), and those with monosomal 
karyotype (median value, 2 years) accounting for 20% and for 8.5% of patients with AK, and for 7% 
and 3% of the whole SMF population, respectively. The impact of MK on survival resulted 
independent from the MYSEC-PM stratification and this indicates to consider this abnormality of 
great relevance for clinical practice. 
 
In conclusion, this study shows that an abnormal karyotype is present in approximately one third 
of SMF and confers a more advanced clinical phenotype. Patients with monosomal karyotype have 
a poor survival independently from the MYSEC-PM risk stratification and need to be identified. 
These findings reinforce the utility of assessing cytogenetics in SMF.  
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Table 1. Demographics of the 376 patients with post polycythemia vera and post essential 
thrombocythemia myelofibrosis according to karyotype. 
 
 
Abnormal  
(N = 128) 
Normal  
(N = 248) 
P value 
Male gender, n. (%) 66 (52) 134 (54) .62 
Age at SMF, median (range), years 66 (33-96) 64 (25-86) .41 
SMF type: PPV MF, n. (%) 76 (40) 112 (60) 
 
.009 
SMF type: PET MF, n. (%) 52 (28) 136 (72) 
WBC, median (range), x 10
9
/L 11.7 (1.7-54.1) 10.4 (1.7-97.3) .47 
Hb, median (range), g/dL 11.1 (6.0-15.7) 11.5 (6.3-15.6) .13 
PLT, median (range), x 10
9
/L 293 (25-959) 365 (20-1420) .004 
Blasts >1%, n. (%) 55 (46) 65 (28) < .001 
Spleen size, median (range), cm 9 (0-29) 6 (0-34) .015 
Constitutional symptoms, n. (%) 63 (51) 91 (37) .013 
Bone marrow fibrosis grade 2, n. (%) 78 (67) 156 (68)  
.91 
Bone marrow fibrosis grade 3, n. (%) 38 (33) 74 (32) 
Driver mutation type:     
CALR, n. (%) 12 (10) 40 (18)  
 
minimum  
 >.2 
JAK2-PET MF, n. (%) 28 (24) 62 (28) 
JAK2-PPV MF, n. (%) 73 (63) 105 (47) 
MPL, n. (%) 3 (3) 10 (4) 
TN, n. (%) 0 (0) 6 (3) 
MYSEC-PM risk category:    
Low, n. (%) 13 (13) 56 (28) 
 
 
.006 
Intermediate-1, n. (%) 51 (50) 89 (44) 
Intermediate-2, n. (%) 22 (21) 39 (20) 
High, n. (%) 17 (16) 16 (8) 
% was calculated on available data. 
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Legend to Figures  
 
Figure 1: Survival estimates of 376 patients with post polycythemia vera and post essential 
thrombocythemia myelofibrosis according to karyotype (normal versus abnormal). Median 
survival was 10.1 years (95% CI: 8.1-NR) in patients with NK and 6.1 years (95% CI 4.8-NR) in those 
with AK (P = .012). Survival curves not overlapping the shaded region are a significantly different at 
the 95% level. 
 
Figure 2: Survival estimates of 376 patients with post polycythemia vera and post essential 
thrombocythemia myelofibrosis according to different cytogenetic abnormalities. Median 
survival was 10.1 years (95% CI: 8.1-NA) for NK, 9.3 years (95% CI: 5.7-NA) for sole abnormality, 7.4 
years (95% CI: 2.5-NA) for double abnormalities, 3.4 years (95% CI: 2.6-NA) for complex karyotype 
without MK, and 2.1 years (95% CI: 1-NA) for MK. 
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Table 1S. List of involved chromosomes according to single, double and complex chromosomal 
abnormalities in 376 patients with post-polycythemia vera and post-essential thrombocythemia 
myelofibrosis.  
Chromosomal Abnormalities  PET-MF PPV-MF Total 
Sole abnormality    
abnormality chromosome n. 1           1 1 2 
abnormality chromosome n. 20          0 1 1 
del(9p) 0 1 1 
del(11q) 1 1 2 
del(13q) 8 7 15 
del(20q) 4 14 18 
del(7q) 1 1 2 
del(9q) 1 0 1 
der(15) t(1;15) 0 2 2 
der(5) t(1;5)   1 0 1 
der(6) t(1;6) 1 0 1 
der(13) 0 1 1 
der(19)                 1 1 2 
der(7)    0 1 1 
der(9) t(1;9) 0 1 1 
inv(10) 1 0 1 
loss of Y      1 0 1 
rearrangement 1q    1 0 1 
t(11;12) 0 1 1 
t(5;12) 1 1 2 
t(6;15)   0 1 1 
t(8;20) 1 0 1 
t(9;22) 0 1 1 
t(X;20) 1 0 1 
trisomy 1q 0 1 1 
trisomy 8 3 3 6 
trisomy 9 2 2 4 
Double abnormality    
der(15) t(1;5) 0 1 1 
trisomy 1q, trisomy 9p 0 1 1 
del(5q), t(3;12) 1 0 1 
del(13q), trisomy 8 0 1 1 
del(20), monosomy 8 0 1 1 
del(20q), t(6;15) 0 1 1 
del(7),+mar 1 0 1 
del(7q), del(20q) 1 0 1 
del(9), del(15) 1 0 1 
del(9q), der(17) t(1;17) 0 1 1 
dup(1q), t(7;12) 0 1 1 
iso(17q), del(7q) 1 0 1 
loss of Y, t(8;22) 1 0 1 
t(9;11), t(6;20) 1 0 1 
t(X;12), t(3;12) 1 0 1 
trisomy 1, der(1;13) 1 0 1 
trisomy 8, del(13q) 0 1 1 
trisomy 8, trisomy 9 1 2 3 
trisomy 9, der(1) 0 1 1 
trisomy 9, trisomy 1 0 1 1 
Complex, not monosomal    
del(3p), +8, +9, +13 0 1 1 
+6, +7, +8, +9, +15 0 1 1 
dup(1), del(6p), del(11q) 0 1 1 
invdup(1p), der(6) t(6;?), der(9) t(9;20), der(14) t(9;14) 0 1 1 
t(10;5;11;9) 0 1 1 
t(2;7;8;12;18) 0 1 1 
der(13), +14, +15 0 1 1 
+9, +8, t(12;14) 1 0 1 
t(3;14;17) 0 1 1 
+8, +9, der(19) t(1;19), del(4), der(13) t(4;13) 0 1 1 
+8, +9, +16 1 0 1 
t(5;9), del(12), del(13) 1 0 1 
del(5q), del(13q), der(20) t(20;?) 1 0 1 
t(1;7), trisomy 9; tetrasomy 21 1 0 1 
abnormality chromosome n. 5, n. 6, n. 10, n. 12 0 1 1 
Complex, monosomal    
del(5q), -18, der(16), t(6;7;18) 0 1 1 
-18, der(18) t(1;18), -22, der(22) t(1;22) 0 1 1 
der(2) t(2;17), del(5q), dic(5;18), add(13p), add(15p),-17 1 0 1 
-1, del(7), del(8), add(11), del(13), -14, -18, add(20), +2mar 0 1 1 
+8, +16, -22, +der(9) t(1;9) 1 0 1 
del(7q), add(17p), add(18q), -21  1 0 1 
del(5q), -6, del(7q), t(12;14), +mar 1 0 1 
del(13q), add(1p), -6, -X, +2, del(4q) 0 1 1 
del(9p), -18, -20 0 1 1 
del(6q), -16, +mar 0 1 1 
+mar1, +mar2,-19 0 1 1 
 
 
 
 
 
 
 
 
 
 
 
Legend to Figure 
 
Figure 1S. Distribution of karyotype (normal and abnormal) among the MYSEC-PM risk 
categories. 
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